- Survival benefit and immune-related adverse events (AEs) from immune checkpoint inhibitors (ICIs) do not differ between elderly and younger patients with NSCLC.
Why this matters
- Treatment-related toxicities from chemotherapy are generally worse in older patients, but an association with age was not established for ICIs.
- 381 patients with NSCLC were treated with ICIs.
- Median follow-up was 19.3 months.
- Funding: The Montreal Cancer Institute.
- 67.5% of patients were aged
- PFS was not significantly different between age groups (3.2 vs 4.3 months, respectively; P=.92).
- OS was not significantly different between groups (13.7 vs 11.6 months; P=.29).
- Rates of all-grade immune-related AEs were not significantly different between groups (57% vs 50%; P=.71).
- After multivariable analysis, Eastern Cooperative Oncology Group Performance Status (ECOG) 0 vs ≥2 was associated with better PFS (HR, 2.58; P<.001 ecog vs was associated with better os p>
- Retrospective study.